Loading...
Continuous glucose monitors (CGM) have been shown to improve glycemic control in people with insulin-treated type 2 diabetes. But do they also have a role in patients who don’t use insulin?
For this industry-sponsored trial, researchers recruited nearly 300 adults with type 2 diabetes and glycosylated hemoglobin (HbA1c) ≥7.5% who were receiving diabetes care through 22 primary care practices in the United States. Participants were randomized to CGM use or routine care for 6 months, with monthly follow-up visits in both groups. Baseline use of noninsulin medications was similar in the two groups.
Over 6 months, the CGM group had a significantly greater decline in mean HbA1c (from 8.8% to 7.2%) than the routine-care group (fro…